Theratechnologies announced that the Brazil Patent and Trademark Office has issued Patent Number 9608799-4 entitled 'Chimeric fatty body-pro-GRF analog with increased biological potency and pharmaceutical formulation' for its lead-compound, tesamorelin. The granting of this patent provides protection in Brazil until December 2019.

"This patent aligns us well in executing one of our top priorities, which is to expand commercialization into various geographies for tesamorelin in HIV-associated lipodystrophy," commented Yves Rosconi, president and chief executive officer of Theratechnologies. "Brazil is a country where there are patients in need and where we can leverage the work already completed for the US regulatory agency. The patent announced today solidifies our approach and reinforces Brazil as an attractive territory for potential partners," concluded Rosconi.

Theratechnologies is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics.